Table IV.

The Occurrence of Residual Morbidity at the End of Follow-up for Patients with Little or No Morbidity at Baseline.

Measure of Morbidity	Treatment Group	n	Patients with Morbidity		Odds Ratio1
			%	95% CI on %	Estimate	95% CI	p-value
Residual Shoulder	ALND	1449	19.0	17.1-21.2	0.64	0.53-0.79	<0.001
Abduction Deficita	SLND	1519	13.2	11.5-15.0
Residual Arm	ALND	1136	27.6	25.1-30.3	0.52	0.43-0.65	<0.001
Volume Differenceb	SLND	1151	16.7	14.6-19.0
Residual Arm	ALND	1336	30.5	28.1-33.1	0.19	0.15-0.23	<0.001
Numbnessc	SLND	1371	7.5	6.2-9.0
Residual Arm	ALND	1329	13.2	11.4-15.1	0.47	0.36-0.62	<0.001
Tinglingc	SLND	1343	6.7	5.4-8.2

¹Odds Ratio of the SLND group compared to the ALND group

^aAbduction Deficit ≥ 5% at 6 Month Follow-up and < 5% at Baseline

^bArm Volume Difference ≥ 5% at 36 Month Follow-up and < 5% at Baseline

^cPresence of Arm Numbness or Tingling at 36 Month Follow-up and None at Baseline